Amanda Jiang
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Background The origins of cutaneous melanoma are often traced to visible precursor lesions (e.g. melanocytic naevi), but approximately two-thirds of melanomas arise from clinically healthy skin with no detectable precursor lesion. The BRAF V600E mutation drives melanoma and naevus formation, but eruptive naevi syndromes and the disproportionate role early-life ultraviolet exposure plays in melanoma risk suggest the presence of a hidden field of oncogene-mutant melanocytes in clinically healthy skin, which may represent an earlier step in tumorigenesis. Objectives To determine whether BRAF V600E-mutant melanocytes were commonly present in nonlesional skin from adults at high risk of melanoma. Methods We examined BRAF V600E mutations in 97 histologically and clinically healthy, nonlesional skin samples from an Australian cohort of individuals at high risk of melanoma. The skin selected was adjacent to a naevus or a prior melanoma site; photodamaged skin proximal (approximately 5 cm) from melanoma excision; photoprotected skin distant from lesions; and low-risk neonatal foreskin-derived melanoblasts. We used immunohistochemistry to locate BRAF V600E-mutant cells in histopathology sections; droplet digital polymerase chain reaction to determine the fractional abundance of BRAF V600E in whole skin; and single-cell RNA sequencing to confirm cells as melanocytes and detect their transcriptional programmes. Results We identified BRAF V600E-mutant melanocytes in skin surrounding naevi and primary melanomas, even years after tumour excision. Fields of BRAF V600E-mutant melanocytes were commonly found in the skin of patients at high risk for melanoma and were up to 20-fold denser and 50% more frequent in tumour-adjacent skin. Field cells exhibited a gene expression profile characteristic of BRAF V600E-induced growth arrest, consistent with dormant yet genetically primed cells. Conclusions There is a reservoir of oncogene-harbouring melanocytes in normal skin. Our findings challenge the prevailing notion that melanocyte expression of BRAF V600E is inherently tumorigenic. The presence of such fields suggests that the scope of melanoma detection and prevention efforts might be extended beyond visible lesions, to encompass potentially precancerous fields of driver-mutant cells. An author video to accompany this article is available online.
Year:
2026
Year:
2026
Acral melanoma, which is not ultraviolet-associated, is the type of melanoma reported most commonly in several non-European-descent populations 1–3 , including in Mexican people 4 . Latin American samples are substantially under-represented in global cancer genomics studies 5 , which directly affects patients in these regions as it is known that cancer risk and incidence may be influenced by ancestry and environmental exposures 6–8 . To address this, we characterized the genome and transcriptome of 123 acral melanoma tumours from 92 Mexican patients—a population notable because of its genetic admixture 9 . Compared with other studies of melanoma, we found fewer mutations in classical driver genes such as BRAF , NRAS or NF1 . Although most patients had predominantly Amerindian genetic ancestry, those with higher European ancestry had increased frequency of BRAF mutations. The tumours with activating BRAF mutations had a transcriptional profile more similar to cutaneous non-volar melanocytes, indicating that acral melanomas in these patients may arise from a distinct cell of origin compared with other tumours arising in these locations. Transcriptional profiling defined three expression clusters; these characteristics were associated with recurrence-free and overall survival. Our study enhances knowledge of this understudied disease and underscores the importance of including samples from diverse ancestries in cancer genomics studies.
Year:
2026
Lentigo maligna (LM) and lentigo maligna melanoma (LMM) arise from chronically sun-damaged skin. LM/LMM incidence continues to increase, particularly in Utah, where melanoma rates are twice the national average. The melanocortin-1 receptor (MC1R) has been studied in melanocyte pigmentation and DNA repair but has yet to be thoroughly investigated in LM/LMM. We investigated allele and genotype frequencies of germline MC1R variants among 175 Utah patients diagnosed with LM/LMM and 402 Utah reference individuals. The comparative analysis demonstrated an increased frequency of the D294H allele (0.046; P = 0.0042) and a decreased frequency of the V60L allele (0.074; P = 0.034) in patients with LM/LMM. The LM/LMM group demonstrated a higher OR compared with the Utah reference group associated with R151C homozygosity compared with heterozygous R151C [OR = 5.6; 95% confidence interval (CI), 0.98–32; P = 0.052] and R151C homozygosity compared with wild type (OR = 5.7; 95% CI, 1.1–30; P = 0.042). D294H heterozygosity was strongly associated with LM/LMM (OR = 3.8; 95% CI, 1.3–11; P = 0.014). Conversely, V60L heterozygosity was less strongly associated with LM/LMM (OR = 0.52; 95% CI, 0.26–1.1; P = 0.072). Stratified analyses showed no significant differences in age or gender across the key MC1R variants studied. These data highlight significant differences in MC1R allele frequencies in patients with LM/LMM, demonstrating that D294H is associated with increased LM/LMM risk, whereas the V60L variant is inversely associated with risk. This study provides the first comprehensive analysis of specific high-risk MC1R variants in patients with LM/LMM in Utah. Significance: Our study is the first comprehensive analysis of MC1R germline variants in patients with LM/LMM in Utah, a region with an exceptionally high melanoma incidence. We draw new risk associations in LM/LMM, identifying an increased risk with the D294H and R151C variants. We also describe a novel inverse association for V60L, warranting further investigation. This study contributes to improved targeted risk stratification and an increased understanding of an understudied melanoma subtype.
Year:
2025
Specific MC1R genotypes confer an increased risk of developing LM/LMM. The heatmaps display the percentage frequencies of MC1R genotypes within two cohorts: ( A ) Mohs LM/LMM cohort and ( B ) the Utah reference group. The heatmaps are color-coded to reflect genotype percentages, with red indicating higher frequencies and green indicating lower frequencies. This comparison highlights the differential distribution of MC1R genotypes between patients with LM/LMM and the Utah reference group. * denotes samples for which we calculated an OR compared with WT or heterozygous/homozygous genotypes.
Year:
2025
MC1R variant allele frequencies vary between the Utah reference group and LM/LMM cohorts. A, Bar graph of MC1R allele frequencies in different populations derived from the dSNP database, N = 24,662–123,831. B, Bar graph comparing the European dbSNP data ( N = 18,644–111,821) with the Utah reference group ( N = 402). C, Bar graph comparing the European dbSNP data ( N = 18,644–111,821) with the LM/LMM cohort ( N = 175). D, Bar graph comparing the MC1R allele frequencies between the LM/LMM cohort ( N = 175) and the Utah reference group ( N = 402). Significance in B–D was assessed using Fisher’s exact test, with a P value P value significance thresholds:
Year:
2025
Lentigo maligna (LM) and lentigo maligna melanoma (LMM) arise from chronically sun-damaged skin. LM/LMM incidence continues to increase, particularly in Utah, where melanoma rates are twice the national average. The melanocortin-1 receptor ( MC1R ) has been studied in melanocyte pigmentation and DNA repair but has yet to be thoroughly investigated in LM/LMM. We investigated allele and genotype frequencies of germline MC1R variants among 175 Utah patients diagnosed with LM/LMM and 402 Utah reference individuals. The comparative analysis demonstrated an increased frequency of the D294H allele (0.046; P = 0.0042) and a decreased frequency of the V60L allele (0.074; P = 0.034) in patients with LM/LMM. The LM/LMM group demonstrated a higher OR compared with the Utah reference group associated with R151C homozygosity compared with heterozygous R151C [OR = 5.6; 95% confidence interval (CI), 0.98–32; P = 0.052] and R151C homozygosity compared with wild type (OR = 5.7; 95% CI, 1.1–30; P = 0.042). D294H heterozygosity was strongly associated with LM/LMM (OR = 3.8; 95% CI, 1.3–11; P = 0.014). Conversely, V60L heterozygosity was less strongly associated with LM/LMM (OR = 0.52; 95% CI, 0.26–1.1; P = 0.072). Stratified analyses showed no significant differences in age or gender across the key MC1R variants studied. These data highlight significant differences in MC1R allele frequencies in patients with LM/LMM, demonstrating that D294H is associated with increased LM/LMM risk, whereas the V60L variant is inversely associated with risk. This study provides the first comprehensive analysis of specific high-risk MC1R variants in patients with LM/LMM in Utah. Significance: Our study is the first comprehensive analysis of MC1R germline variants in patients with LM/LMM in Utah, a region with an exceptionally high melanoma incidence. We draw new risk associations in LM/LMM, identifying an increased risk with the D294H and R151C variants. We also describe a novel inverse association for V60L, warranting further investigation. This study contributes to improved targeted risk stratification and an increased understanding of an understudied melanoma subtype.
Year:
2025
Purpose: Clinical evidence indicates that treatment with estrogens elicits anticancer effects in ∼30% of patients with advanced endocrine-resistant estrogen receptor α (ER)-positive breast cancer. Despite the proven efficacy of estrogen therapy, its mechanism of action is unclear and this treatment remains underused. Mechanistic understanding may offer strategies to enhance therapeutic efficacy. Experimental Design: We performed genome-wide CRISPR/Cas9 screening and transcriptomic profiling in long-term estrogen-deprived ER+ breast cancer cells to identify pathways required for therapeutic response to the estrogen 17β-estradiol (E2). We validated findings in cell lines, patient-derived xenografts (PDX), and patient samples, and developed a novel combination treatment through testing in cell lines and PDX models. Results: Cells treated with E2 exhibited replication-dependent markers of DNA damage and the DNA damage response prior to apoptosis. Such DNA damage was partially driven by the formation of DNA:RNA hybrids (R-loops). Pharmacologic suppression of the DNA damage response via PARP inhibition with olaparib enhanced E2-induced DNA damage. PARP inhibition synergized with E2 to suppress growth and prevent tumor recurrence in BRCA1/2 -mutant and BRCA1 /2-wild-type cell line and PDX models. Conclusions: E2-induced ER activity drives DNA damage and growth inhibition in endocrine-resistant breast cancer cells. Inhibition of the DNA damage response using drugs such as PARP inhibitors can enhance therapeutic response to E2. These findings warrant clinical exploration of the combination of E2 with DNA damage response inhibitors in advanced ER+ breast cancer, and suggest that PARP inhibitors may synergize with therapeutics that exacerbate transcriptional stress.
Year:
2025
Acral melanoma (AM) is an aggressive melanoma variant that arises from palmar, plantar, and nail unit melanocytes. Compared to non-acral cutaneous melanoma (CM), AM is biologically distinct, has an equal incidence across genetic ancestries, typically presents in advanced stage disease, is less responsive to therapy, and has an overall worse prognosis. Independent analysis of published genomic and transcriptomic sequencing identified that receptor tyrosine kinase (RTK) ligands and adapter proteins are frequently amplified, translocated, and/or overexpressed in AM. To target these unique genetic changes, a zebrafish acral melanoma model was exposed to a panel of narrow and broad spectrum multi-RTK inhibitors, revealing that dual FGFR/VEGFR inhibitors decrease acral-analogous melanocyte proliferation and migration. The potent pan-FGFR/VEGFR inhibitor, Lenvatinib, uniformly induces tumor regression in AM patient-derived xenograft (PDX) tumors but only slows tumor growth in CM models. Unlike other multi-RTK inhibitors, Lenvatinib is not directly cytotoxic to dissociated AM PDX tumor cells and instead disrupts tumor architecture and vascular networks. Considering the great difficulty in establishing AM cell culture lines, these findings suggest that AM may be more sensitive to microenvironment perturbations than CM. In conclusion, dual FGFR/VEGFR inhibition may be a viable therapeutic strategy that targets the unique biology of AM.
Year:
2024
Purpose: Clinical evidence indicates that treatment with estrogens elicits anti-cancer effects in ~30% of patients with advanced endocrine-resistant estrogen receptor alpha (ER)-positive breast cancer. Despite the proven efficacy of estrogen therapy, its mechanism of action is unclear and this treatment remains under-utilized. Mechanistic understanding may offer strategies to enhance therapeutic efficacy. Experimental Design: We performed genome-wide CRISPR/Cas9 screening and transcriptomic profiling in long-term estrogen-deprived (LTED) ER+ breast cancer cells to identify pathways required for therapeutic response to the estrogen 17b-estradiol (E2). We validated findings in cell lines, patient-derived xenografts (PDXs), and patient samples, and developed a novel combination treatment through testing in cell lines and PDX models. Results: Cells treated with E2 exhibited replication-dependent markers of DNA damage and the DNA damage response prior to apoptosis. Such DNA damage was partially driven by the formation of DNA:RNA hybrids (R-loops). Pharmacological suppression of the DNA damage response via poly(ADP-ribose) polymerase (PARP) inhibition with olaparib enhanced E2-induced DNA damage. PARP inhibition synergized with E2 to suppress growth and prevent tumor recurrence in BRCA1/2-mutant and BRCA1/2-wild-type cell line and PDX models. Conclusions: E2-induced ER activity drives DNA damage and growth inhibition in endocrine-resistant breast cancer cells. Inhibition of the DNA damage response using drugs such as PARP inhibitors can enhance therapeutic response to E2. These findings warrant clinical exploration of the combination of E2 with DNA damage response inhibitors in advanced ER+ breast cancer, and suggest that PARP inhibitors may synergize with therapeutics that exacerbate transcriptional stress.
Year:
2024
Year:
2023
Year:
2021
Year:
2021
Collaborators (16)
Katie Lee
The University of Queensland
Deborah Neklason
Research Professor
University of Utah
Rachel Belote
Assistant Professor
Ohio State University
Richard White
Professor
University of Oxford
Dekker Deacon
Assistant Professor
University of Utah
John Hyngstrom
Associate Professor, Surgical Oncology
Rush University Medical Center
Bing-Jian Feng
Research Associate Professor
University of Utah
Mitchell S. Stark
Associate Professor/Group Leader/Principal Research Fellow
University of Queensland
Douglas Grossman
Professor
University of Utah Health Sciences Center
Zewen Kelvin Tuong
University of Queensland
Robert Judson‐Torres
-
Thomas Zangle
Associate Professor
University of Utah
Ingrid FERREIRA
Cliniques Universitaires Saint-Luc
Jessica Donigan
Assistant Professor
University of Utah
Nelly Cruz
Senior Research Scientist
Sloan Kettering Institute
Kenneth Boucher
Research Professor
University of Utah
Make your next move.
Prepare your application
Review drafts before you send them.